ATXI · XBRL financial data

Avenue Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ATXI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	0	0	0*	—	1,404	0	0*	—	0
Research and development	907	982*	2,392	1,361	2,327	565*	411	192	177	257*	200	247
General and administrative	1,161	1,137*	1,316	1,462	829	1,031*	1,494	915	547	698*	514	460
Total operating expenses	—	—	—	2,823	3,156	1,596*	—	1,107	724	752*	—	707
Operating income (loss)	(2,068)	(2,119)*	(3,708)	(2,823)	(3,156)	(1,596)*	(1,905)	297	(724)	(752)*	(714)	(707)
Interest income	9	22*	49	52	51	24*	32	31	34	25*	18	17
Income tax expense (benefit)	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net income (loss)	526	—	(4,340)	(2,692)	(3,076)	(1,544)*	(1,852)	335	(683)	(709)*	(695)	(690)
Earnings per share, basic‡ USD per share	4.50	—	(1,155.00)	(6.43)	(1.92)	—	(0.62)	0.11	(0.21)	(0.22)*	(0.21)	(0.21)
Earnings per share, diluted‡ USD per share	4.50	—	—	—	—	—	—	—	—	—	—	—
Weighted average shares, basic‡ thousands of shares	108	—	7	1,118	1,600	—	2,971	3,184	3,184	3,184*	3,294	3,295
Weighted average shares, diluted‡ thousands of shares	109	—	—	—	—	—	—	—	—	—	—	—

‡ Per-share figures and share counts are adjusted for the 1-for-75 stock split (December 2024); filings made before it reported them unadjusted.
† Share count changed about 1/47 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 114x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ATXI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	161	1,783	3,194	4,919	2,597	2,594	3,502	3,326	3,709	2,855	2,417	1,942
Prepaid and other current assets	18	67	116	69	28	78	92	35	16	76	51	34
Total assets	502	1,850	3,310	4,988	2,625	2,672	3,594	4,161	3,725	2,931	2,468	1,976
Accounts payable	296	78	—	—	—	155	—	—	—	—	—	—
Total current liabilities	5,024	1,196	1,412	1,161	973	816	1,262	1,329	1,422	1,099	1,270	1,407
Total liabilities	5,024	1,196	1,412	1,161	973	816	1,262	1,329	1,422	1,099	1,270	1,407
Accumulated deficit	(91,568)	(90,928)	(95,268)	(97,960)	(101,036)	(102,580)	(104,432)	(104,097)	(104,780)	(105,489)	(106,184)	(106,874)
Total stockholders' equity	(3,650)	1,582	2,836	4,764	2,610	2,797	3,510	4,058	3,557	1,832	1,198	569
Total liabilities and equity	502	1,850	3,310	4,988	2,625	2,672	3,594	4,161	3,725	2,931	2,468	1,976
Common shares outstanding (cover page)‡ thousands of shares	177	590	13	1,431	1,912	3,150	3,184	3,184	3,184	3,295	3,295	3,295

‡ Per-share figures and share counts are adjusted for the 1-for-75 stock split (December 2024); filings made before it reported them unadjusted.
† Share count changed about 1/47 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 114x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (ATXI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24†Mar 31, 2024	Q2 FY24†Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	526	—	(4,340)	(2,692)	(3,076)	(1,544)*	(1,852)	335	(683)	(709)*	(695)	(690)
Stock-based compensation	561*	307*	191	192*	331*	522*	185	175*	163*	142*	61	61*
Net cash from operating activities	(889)*	(2,324)*	(3,120)	(2,253)*	(2,889)*	(764)*	(1,186)	(176)*	383*	(854)*	(438)	(475)*
Net cash from investing activities	(1,000)*	0*	—	—	0*	0*	—	—	—	—	—	—
Proceeds from issuing common stock	0*	0*	0	295*	567*	761*	2,094	0*	0*	0*	0	0*
Share repurchases	—	year only	—	—	—	—	—	—	—	—	—	—
Net cash from financing activities	479*	3,946*	4,531	3,978*	567*	761*	2,094	0*	0*	0*	0	0*

† Share count changed about 1/47 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 114x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Avenue Therapeutics	1,942	0	(475)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
China Foods Holdings	16	0	(94)*	20.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1,629	not reported	(1,394)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
NovAccess Global	21	0*	(55)*	61.7M	0.4 quarters	Q4 FY24 10-KSep 30, 2024
Eloxx Pharmaceuticals	61,960	not reported	(4,789)*	4.0M	12.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.